Navigation Links
PTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results

SOUTH PLAINFIELD, N.J., Aug. 12, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended June 30, 2013.

(Logo: )

"The first half of the year was a very exciting time for PTC. We successfully completed an IPO raising gross proceeds of more than $144 million. With over $165 million in cash on our balance sheet at the end of the quarter, we are now well capitalized to continue the late-stage clinical development of our lead product candidate, ataluren, in nonsense mutation Duchenne muscular dystrophy and cystic fibrosis," said Stuart Peltz, PhD, Chief Executive Officer, PTC Therapeutics, Inc. "We began enrolling patients in our Phase 3 nmDMD clinical trial earlier this year and we plan to begin enrollment in our Phase 3 nmCF clinical trial in the first half of 2014.  We are also excited about the progress that is being made in our SMA program that is partnered with Roche where we recently announced the selection of a development candidate."

Key Recent Accomplishments

  • Successful Completion of Initial Public Offering (IPO): In June 2013, PTC completed its IPO selling approximately 9.6 million shares of common stock at a public offering price of $15 per share, resulting in approximately $144.4 million in gross proceeds to the company, before deducting underwriting discounts and commissions and other offering expenses.
  • Initiated Confirmatory Phase 3 Study of Ataluren in nmDMD: In April 2013, PTC initiated a confirmatory Phase 3 clinical trial evaluating ataluren as a potential treatment for patients with Duchenne muscular dystrophy due to a nonsense mutation (nmDMD). The study is on-track to complete enrollment by mid-2014 with country approvals for the trial and clinical trial site initiation proceeding according to plan. The Phase 3 study is expected to be conducted at 53 clinical sites across 18 countries.
  • Submitted Responses to Day 120 Questions for MAA Submission: Following the October 2012 submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for conditional approval of ataluren in nmDMD, the EMA provided a list of questions to PTC regarding its application, known as the Day 120 Questions. In July 2013, PTC submitted responses to the Day 120 Questions to the EMA. The company anticipates a response from the Committee for Medicinal Products for Human Use, or CHMP, on the MAA submission for conditional approval of ataluren for the treatment of nmDMD by the end of 2013.
  • Selected Lead Candidate for SMA Program: On August 8, 2013, in collaboration with its partners, the SMA Foundation and Roche, PTC declared a lead development candidate in the spinal muscular atrophy (SMA) program. Selection of the development candidate triggered a $10 million milestone payment by Roche to PTC, which will be recognized as revenue in the third quarter of 2013. This milestone is important for moving this program forward and evidences the value of PTC's splicing platform technology.
  • Second Quarter 2013 Financial Highlights

  • Cash, cash equivalents, and marketable securities totaled $165.7 million at June 30, 2013 compared to $2.7 million at December 31, 2012.
  • Total operating expenses increased to $21.3 million for the second quarter of 2013, including $1.9 million in stock based compensation expense, from $15.1 million for the second quarter of 2012, including $0.6 million in stock based compensation expense. The increase was primarily due to higher research and development expenses related to the initiation of the Phase 3 clinical trial of ataluren for the treatment of nmDMD, as well as higher general and administrative expenses related to public company expenses and pre-commercial activities.
  • Net loss attributable to common shareholders for the second quarter of 2013 was $14.6 million compared to a net income attributable to common shareholders for the second quarter of 2012 of $153.5 million. In 2012, the company recorded a gain of $160.0 million on exchange of convertible preferred stock in connection with a recapitalization. 
  • In July 2013, the company paid in full the outstanding principal and interest balance of $2.6 million under promissory notes issued related to a secured debt facility with a syndicate of two lenders.
  • Today's Conference Call and Webcast ReminderThe PTC management team will host a conference call to discuss the company's financial results and recent and upcoming developments today, Monday, August 12, 2013, at 4:30 p.m. ET. The call can be accessed by dialing 877-303-9216 (domestic) or 973-935-8152 (international) five minutes prior to the start of the call and providing the passcode 24942756.

    The live, listen-only webcast of the conference call can also be accessed by visiting the "Investors Relations" section of the company's website at A replay of the webcast will be archived on the PTC website for 30 days following the call.


    PTC is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. While PTC's discovery programs are directed at targets in multiple therapeutic areas, PTC is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. For more information on the company, please visit our website

    FORWARD LOOKING STATEMENTS:Any statements in this press release about future expectations, plans and prospects for the company, including statements about the development of ataluren, such as the timing and conduct of the company's Phase 3 clinical trial, the timing and likelihood of conditional approval of ataluren, pre-commercial activities, the advancement of  the company's earlier stage pipeline and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates, the sufficiency of our cash resources and need for additional financing and other factors discussed in the "Risk Factors" section of the final prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date of this release. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this release.PTC THERAPEUTICS, INC.Statements of OperationsThree Months Ended June 30,Six Months Ended June 30,2012201320122013Revenues:Collaboration revenue




    11,939,954Grant revenue1,520,764


    2,055,922Total revenues and non-cash cancellation revenue7,585,177


    13,995,876Operating expenses:Research and development11,918,999


    25,968,919General and administrative3,164,385


    11,056,302Total operating expenses15,083,384


    37,025,221Loss from operations(7,498,207)


    (23,029,345)Interest expense, net(335,081)


    (6,276,229)Other income (expense), net1,765,216


    34,461Net loss(6,068,072)


    (29,271,113)Deemed dividend—


    (18,248,768)Gain on exchange of convertible preferred stock inconnection with recapitalization159,954,069


    3,390,750Less beneficial conversion charge(377,787)


    —Net income (loss) attributable to common stockholders




    (44,129,131) PTC THERAPEUTICS, INC.Summary Balance SheetDecember 31, June 30,20122013Cash, cash equivalents and marketable securities 


    $165,678,055Total Assets


    175,468,084Total Liabilities


    22,548,444Total Liabilities, convertible preferred stock and stockholders' (deficit) equity



    SOURCE PTC Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    (Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
    (Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
    (Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
    Breaking Medicine Technology:
    (Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
    (Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
    (Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
    (Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
    Breaking Medicine News(10 mins):